AMG 208

DRUG2 trials

Sponsors

Amgen, M.D. Anderson Cancer Center

Conditions

Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsProstate CancerTumors

Phase 1

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

CompletedNCT00813384

AmgenAdvanced Malignancy, Advanced Solid Tumors, Cancer +3

Start: 2008-12-31End: 2014-12-31Updated: 2014-12-16

Phase 2

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

WithdrawnNCT02420587

M.D. Anderson Cancer CenterProstate Cancer

Start: 2014-10-31Updated: 2015-04-20